GPC3 and hepatocellular carcinoma: However, recent interests in immunotherapy were stimulated by the success of oncolytic viral gene therapy using JX-594 [6], the use of anti-Glypican-3 (anti-GPC3) antibodies to neutralize GPC3 antigens present on 80% of HCC cells [7], and CTLA-4 blockade clinical trials [8].